We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 21, 2021

Adjuvant Pembrolizumab Cuts Recurrence in Stage II Melanoma

Compared with placebo, pembrolizumab prolonged regression-free survival in resected high-risk stage IIB and IIC melanoma

HealthDay

 

Further Reading